Payment overview · 2025
General Payments
$393.79
25 reported records · 7 companies
Healthcare provider profile · identity verified
James Winbush, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ANDERSON, SC · NPI 1912008806
Verified facts
What the public records show
CMS Open Payments records show James Winbush, MD received $393.79 in general payments during 2025 across 25 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 41.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $162.46 | 41.3% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.12 | 28.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.24 | 9.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.11 | 8.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.60 | 5.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.88 | 3.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.38 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.79 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $162.46 | 17 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.12 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $34.11 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 82 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 198 | 80 |
| Azithromycin | Azithromycin | 180 | 102 |
| Dexamethasone | Dexamethasone | 149 | 94 |
| Omeprazole | Omeprazole | 119 | 54 |
| Montelukast Sodium | Montelukast Sodium | 101 | 50 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 60 |
| Prednisone | Prednisone | 93 | 57 |
| Gabapentin | Gabapentin | 91 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 88 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 18 |
| Furosemide | Furosemide | 83 | 37 |
| Mounjaro | Tirzepatide | 82 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 33 |
| Lisinopril | Lisinopril | 78 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 33 |
| Jardiance | Empagliflozin | 71 | 23 |
| Methylprednisolone | Methylprednisolone | 70 | 58 |
| Losartan Potassium | Losartan Potassium | 68 | 26 |
| Pregabalin | Pregabalin | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 21 |
| Simvastatin | Simvastatin | 54 | 20 |
| Ezetimibe | Ezetimibe | 51 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 30 |
| Baclofen | Baclofen | 44 | 31 |
| Carvedilol | Carvedilol | 44 | 21 |
| Ozempic | Semaglutide | 43 | 13 |
| Tramadol Hcl | Tramadol Hcl | 43 | 20 |
| Trazodone Hcl | Trazodone Hcl | 42 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 16 |
| Eliquis | Apixaban | 39 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 17 |
| Levofloxacin | Levofloxacin | 38 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | 13 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 18 |
| Allopurinol | Allopurinol | 34 | 15 |
| Clonidine Hcl | Clonidine Hcl | 34 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 34 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Nifedipine Er | Nifedipine | 30 | 14 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Fluconazole | Fluconazole | 27 | 15 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 26 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 16 |
| Metronidazole | Metronidazole | 24 | 18 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | 13 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Metformin Hcl | Metformin Hcl | 21 | 12 |
| Nabumetone | Nabumetone | 21 | 16 |
| Buspirone Hcl | Buspirone Hcl | 20 | 12 |
| Farxiga | Dapagliflozin Propanediol | 20 | 11 |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 14 |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | 11 |
| Famotidine | Famotidine | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393.79 · 25 records | Bayer Healthcare Pharmaceuticals Inc. | ELIQUIS, Kerendia, MOUNJARO, NUZYRA, Ozempic, Rybelsus, VOWST, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error